Igor Puzanov

Roswell Park Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile

0.104Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Risk of further progression or death among durable progression-free survivors with melanoma in PD-1 blockade trials: Implications for imaging surveillance.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9529

Top 78%

0.104DataRank

Top 78%1 citations

Changchuan Jiang, Kristopher Attwood, Stuthi Perimbeti, Chen Hu, Igor Puzanov +1 more

Papers

Driven by 32 papers — median percentile 22. Top paper: “Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study”.

Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study

Cancer(2020)10.1002/cncr.32883

N/A

4.9DataRank · unranked

150 citations

Emily Bergsland, Bert H. O’Neil, Armando Santoro, Jan H.M. Schellens, Roger B. Cohen +15 more

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Neuro-Oncology(2021)10.1093/neuonc/noab094

N/A

4.0DataRank · unranked

126 citations

Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid +18 more

Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

European Journal of Cancer(2020)10.1016/j.ejca.2020.11.010

N/A

3.9DataRank · unranked

100 citations

Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, Adil Daud +18 more

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

British Journal of Cancer(2020)10.1038/s41416-020-01041-x

N/A

2.6DataRank · unranked

90 citations

Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla +15 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2007

N/A

0.965DataRank · unranked

32 citations

Arun S. Singh, Stephen P. Anthony, Mike Sterba, Chao Zhang, John H. Healey +19 more

Risk of further progression or death among durable progression-free survivors with melanoma in PD-1 blockade trials: Implications for imaging surveillance.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9529

Top 78%

0.104DataRank

Top 78%1 citations

Changchuan Jiang, Kristopher Attwood, Stuthi Perimbeti, Chen Hu, Igor Puzanov +1 more

Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial

Kidney Cancer Journal(2021)10.52733/kcj19n3-a1

N/A

0DataRank · unranked

6 citations

Qian Yang, Andrea Carmack, Shiqi Zhang, Wen‐Chi Foo, Tim Eisen +15 more

Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness

Essays in Biochemistry(2022)10.1042/ebc20220003

N/A

0DataRank · unranked

23 citations

Wen Li, Igor Puzanov, David W. Goodrich, Gurkamal Chatta, Dean G. Tang +1 more

Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

Cancers(2022)10.3390/cancers14174334

N/A

0DataRank · unranked

5 citations

Cassandra Hennessy, Alicia Beeghly, Benjamin French, Dimpy P. Shah, Sarah Croessmann +42 more

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)

Journal of Translational Medicine(2023)10.1186/s12967-023-04329-7

N/A

0DataRank · unranked

11 citations

Antonio Avallone, Carlo Bifulco, Sergio Bracarda, Joshua Brody, Leisha A. Emens +19 more

Intratumoral and Microenvironmental Heterogeneity in Patient Outcome Prediction

JCO Precision Oncology(2023)10.1200/po.22.00698

N/A

0DataRank · unranked

4 citations

Alvin P. Makohon-Moore, Igor Puzanov, Robert A. Beckman

Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.11.25.568612

N/A

0DataRank · unranked

1 citations

Yunfei Wang, Xiaozhuo Liu, Shan Wu, Moyi Wang, Steven G. Turowski +9 more

Data from Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors

(2023)10.1158/1078-0432.c.6519480

N/A

0DataRank · unranked

0 citations

Wooin Lee, Alice P. Chen, M. Wade Calcutt, David L. Hachey, W. Vermeulen +6 more

Data from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

(2023)10.1158/1078-0432.c.6530279

N/A

0DataRank · unranked

0 citations

Manu Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K. Witkiewicz, Erik S. Knudsen +14 more

Reply to M. Younes

JCO Precision Oncology(2023)10.1200/po.23.00170

N/A

0DataRank · unranked

0 citations

Alvin P. Makohon-Moore, Igor Puzanov, Robert A. Beckman

Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008735

N/A

0DataRank · unranked

79 citations

Omid Hamid, Krishna V. Komanduri, Rodabe N. Amaria, Marcus O. Butler, John B.A.G. Haanen +6 more

Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises

International Journal of Molecular Sciences(2024)10.3390/ijms25042123

N/A

0DataRank · unranked

31 citations

Yunfei Wang, Xiaozhuo Liu, Shan Wu, Moyi Wang, Steven G. Turowski +9 more

Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells

Cell stem cell(2024)10.1016/j.stem.2024.05.008

N/A

0DataRank · unranked

20 citations

Jie Wang, Mark D. Long, Spencer R. Rosario, Amanda Tracz, Yibing Ji +16 more

Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers

Communications Medicine(2024)10.1038/s43856-024-00540-9

N/A

0DataRank · unranked

10 citations

Sunitha Shyam Sunder, Igor Puzanov, Scott H. Olejniczak, Saraswati Pokharel, Umesh C. Sharma +1 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100751

N/A

0DataRank · unranked

4 citations

Jialiang Liu, Hong Mu-Mosley, Farjana Fattah, Jason Y. Park, Jeffrey A. SoRelle +17 more

The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study

Cancer(2024)10.1002/cncr.35247

N/A

0DataRank · unranked

3 citations

Tianyi Sun, Deepak Ravindranathan, Clara Hwang, Nino Balanchivadze, Sunny R. K. Singh +52 more

Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers

Journal of Oncology Research and Therapy(2024)10.29011/2574-710x.10224

N/A

0DataRank · unranked

1 citations

Dale J. Hedges, Aik Choon Tan, Paulo C. Rodrı́guez, Vineeth Sukrithan, Aakrosh Ratan +10 more

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors

Nature Communications(2025)10.1038/s41467-025-65016-3

N/A

0DataRank · unranked

5 citations

Tingyi Li, Islam Eljilany, Alex C. Soupir, Michael D. Radmacher, Phaedra Agius +17 more

Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2381

N/A

0DataRank · unranked

145 citations

Manu Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K. Witkiewicz, Erik S. Knudsen +14 more

Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1265

N/A

0DataRank · unranked

126 citations

Igor Puzanov, Jean‐Yves Blay, Ian Chau, A. Craig Lockhart, Noopur Raje +11 more

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000331

N/A

0DataRank · unranked

125 citations

Kristina Navrazhina, Fei Ding, Roma Bhatia, Katy K. Tsai, Kelly Abbate +23 more

A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.06.13.095844

N/A

0DataRank · unranked

3 citations

Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood +11 more

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

Nature Communications(2021)10.1038/s41467-021-21619-0

N/A

0DataRank · unranked

188 citations

Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood +11 more

Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002553

N/A

0DataRank · unranked

67 citations

Poornima Subramanian, Yan Yatsynovich, David M. Jacobs, Maya R. Chilbert, Umesh C. Sharma +17 more

Igor Puzanov

Indexed papers

Top data-sharing exemplar

Papers